Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

324.71 +0.48 (+0.15%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
18 19 Next >
Eli Lilly Posts Mixed Third Quarter, But Raises 2021 Sales Guidance
Eli Lilly's third-quarter earnings narrowly missed, though sales came in ahead. 
Via Investor's Business Daily
Eli Lilly Q3 Earnings Beat Estimates, Boosts FY21 Guidance On Higher COVID-19 Therapy Sales
Eli Lilly And Co (NYSE: LLY) has posted Q3 sales of $6.77 billion, beating the consensus of $5.70 billion and increasing 18% Y/Y. Higher sales were driven by a 17... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M... 
Via Benzinga
Eli Lilly: Q3 Earnings Insights
Eli Lilly (NYSE:LLY) reported its Q3 earnings results on Tuesday, October 26, 2021 at 06:25 AM. Here's what investors need to know about the announcement. Earnings Eli... 
Via Benzinga
Earnings Scheduled For October 26, 2021
Companies Reporting Before The Bell • Veoneer (NYSE:VNE) is likely to report quarterly loss at $0.83 per share on revenue of $408.69 million. • Aarons (NYSE:AAN)... 
Via Benzinga
Where Eli Lilly Stands With Analysts
Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE: 
Via Benzinga
A Peek Into The Markets: US Stock Futures Rise Ahead Of Big Earnings
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at record highs in the previous session. Investors are... 
Via Benzinga
Topics Stocks
Exposures US Equities
7 Stocks To Watch For October 26, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects General Electric Company (NYSE: GE) to report quarterly earnings at $0.43 per share on revenue of... 
Via Benzinga
Earnings Preview For Eli Lilly
Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Tuesday, 2021-10-26. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Key takeaways Four rounds of fundraising together with IPO proceeds have given the Abbisko a cumulative war chest of almost $500 million Company is betting a significant portion... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Price Over Earnings Overview: Eli Lilly
In the current market session, Eli Lilly Inc. (NYSE:LLY) is trading at $240.60, after a 0.23% decrease. However, over the past month, the stock spiked by 3.94%, and... 
Via Benzinga
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach. 
Via Investor's Business Daily
Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?
Molnupiravir seems likely to shake up the COVID-19 antibody therapy market. 
Via The Motley Fool
Exposures COVID-19
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
Could This Be the Next Blockbuster Indication for Eli Lilly?
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata. 
Via The Motley Fool
Exposures COVID-19
2 Stocks That Could Grow Your Portfolio Over the Next Decade
These reliable healthcare companies have a lot to offer investors. 
Via The Motley Fool
28 Stocks To Benefit From Inflation, According To Jim Cramer
On CNBC’s “Ma... 
Via Benzinga
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday fo... 
Via Benzinga
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit... 
Via Benzinga
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB... 
Via Talk Markets
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
Upgrades According to Vertical Research, the prior rating for C.H. Robinson Worldwide Inc (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc lifted Netflix, Inc. (NASDAQ: NFLX) price target from $645 to $670. Netflix shares rose 0.1% to $633.00 in pre-market trading. JMP Securities raised ServiceNow, Inc. (... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
3 Top Stocks That Have Been Paying Dividends for a Combined 467 Years
Eli Lilly, Exxon Mobil, and Bank of Montreal are among the most stable income stocks you can find. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.